UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: December 4, 2014
(Date of earliest event reported)
TENET HEALTHCARE CORPORATION
(Exact name of Registrant as specified in its charter)
|
Nevada |
|
1-7293 |
|
95-2557091 |
|
(State of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
1445 Ross Avenue, Suite 1400
Dallas, Texas 75202
(Address of principal executive offices, including zip code)
(469) 893-2200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 4, 2014, the Board of Directors (the “Board”) of Tenet Healthcare Corporation (the “Company”) expanded the size of the Board from nine to ten members and elected Freda C. Lewis-Hall, M.D. as an independent member of the Board. Dr. Lewis-Hall has not yet been appointed to serve on any committees of the Board.
Dr. Lewis-Hall will participate in the non-employee director compensation programs described under “Director Compensation” in the Company’s proxy statement filed with the SEC on March 28, 2014. There is no arrangement or understanding between Dr. Lewis-Hall and any other persons pursuant to which she was selected as a director. In addition, Dr. Lewis-Hall is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933.
A copy of the Company’s press release announcing Dr. Lewis-Hall’s appointment is filed as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release issued on December 4, 2014
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
TENET HEALTHCARE CORPORATION | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Paul A. Castanon |
|
|
|
Paul A. Castanon |
|
|
|
Vice President, Deputy General Counsel and |
|
|
|
Corporate Secretary |
Date: December 4, 2014